Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -55.94 | 21.65 | 5.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 18.18 | 13.21 | 14.72 | 13.35 | 14.19 | 17.45 | 23.17 | 11.83 | 37.80 | 54.31 | 22.42 | 12.95 | 27.43 | 26.47 | 44.76 | 74.67 | 94.26 | 210.54 | 243.73 | 369.83 | 1956.20 |
| — | -24.3% | -36.5% | +12.8% | -62.5% | -67.9% | +3.3% | -8.6% | +37.8% | +105.2% | -49.9% | -82.7% | -70.9% | -87.4% | -81.6% | -79.8% | -95.2% | -87.8% | -89.5% | -91.2% | +165.2% | |
| P/B Ratio | — | 12.69 | 30.21 | — | — | — | — | — | — | — | — | — | — | 77.38 | 35.97 | 25.97 | 12.77 | 8.53 | 9.89 | 8.20 | 8.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | +806.7% | +263.6% | +216.7% | +45.7% | -17.2% | +14.6% | -23.3% | +2.5% | |
| P/FCF | 288.36 | 16.09 | — | 48.57 | 1443.48 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 65.59 | 127.78 | 228.78 | 206.44 | — | — | 438.85 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | -47.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 70.39 | 194.44 | 95.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.1% | 90.6% | 91.4% | 88.9% | 89.5% | 80.1% | 82.6% | 91.9% | 80.6% | 68.2% | 92.1% | 85.9% | 84.6% | 72.7% | 86.2% | 77.7% | 88.9% | 82.4% | 37.8% | 28.1% | 100.0% |
| — | +13.1% | +10.6% | -3.3% | +11.0% | +17.5% | -10.3% | +7.1% | -4.7% | -6.3% | +6.8% | +10.6% | -4.8% | -11.7% | +128.1% | +176.8% | -11.1% | -17.6% | -62.2% | +100.1% | +104.5% | |
| Operating Margin | -18.9% | 18.4% | 10.1% | 4.0% | 5.1% | -33.5% | -103.2% | 0.2% | -167.3% | -370.2% | -51.2% | -26.6% | -279.8% | -297.2% | -427.8% | -643.7% | -945.1% | -2303.5% | -1875.1% | -2299.0% | -8709.1% |
| — | +154.9% | +109.7% | +1715.8% | +103.1% | +90.9% | -101.4% | +100.8% | +40.2% | -24.6% | +88.0% | +95.9% | +70.4% | +87.1% | +77.2% | +72.0% | +89.1% | +80.0% | +88.8% | +87.1% | -204.6% | |
| Net Margin | -31.7% | 61.0% | 255.2% | -13.6% | -28.5% | -24.6% | -93.7% | -22.1% | -171.5% | -303.9% | -136.6% | -63.1% | -337.7% | -256.2% | -330.2% | -905.9% | -1105.0% | -1320.1% | -1838.0% | -2165.9% | -7219.0% |
| — | +348.1% | +372.3% | +38.7% | +83.4% | +91.9% | +31.4% | +64.9% | +49.2% | -18.6% | +58.6% | +93.0% | +69.4% | +80.6% | +82.0% | +58.2% | +84.7% | +90.0% | +78.2% | +91.7% | -63.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | 21.9% | 392.8% | — | — | — | — | — | — | — | — | — | — | -104.7% | -51.5% | -58.0% | -31.9% | -12.7% | -16.1% | -11.3% | -9.6% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -724.2% | -219.5% | -413.5% | -233.7% | +29.6% | -110.8% | +27.2% | +43.9% | |
| ROA | -17.7% | 9.8% | 38.7% | -2.7% | -5.4% | -3.6% | -8.4% | -3.4% | -10.7% | -14.0% | -16.1% | -10.2% | -19.1% | -13.6% | -10.8% | -17.6% | -13.0% | -6.0% | -10.2% | -9.3% | -7.8% |
| — | +371.3% | +558.0% | +20.0% | +49.2% | +74.2% | +47.5% | +66.9% | +44.0% | -3.3% | -49.2% | +41.7% | -47.1% | -125.6% | -5.8% | -89.5% | -66.4% | +59.3% | -57.9% | +32.5% | +48.5% | |
| ROIC | -69.1% | 5.0% | 4.2% | 7.6% | 7.8% | -31.7% | -47.2% | 0.2% | -91.5% | -98.3% | -23.3% | -15.4% | -61.5% | -60.7% | -43.3% | -30.6% | -25.7% | -25.4% | -18.5% | -16.1% | -18.0% |
| — | +115.9% | +108.8% | +3304.0% | +108.5% | +67.7% | -102.4% | +101.4% | -48.7% | -61.8% | +46.0% | +49.6% | -139.6% | -139.3% | -133.8% | -90.1% | -42.5% | -16.3% | +25.8% | +36.4% | +24.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.31 | 1.84 | — | — | — | — | — | — | — | — | — | — | 7.80 | 3.02 | 1.93 | 1.23 | 0.84 | 0.70 | 0.24 | 0.10 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | +826.0% | +329.3% | +712.6% | +1089.9% | +473.5% | +485.8% | +116.6% | +194.4% | |
| Debt / EBITDA | — | 6.61 | 30.42 | 59.76 | 54.19 | — | — | 176.33 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | -66.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.04 | 2.99 | 1.00 | 1.04 | 1.03 | 1.02 | 1.04 | 1.17 | 1.16 | 0.74 | 0.83 | 0.95 | 3.44 | 3.52 | 4.08 | 5.39 | 7.56 | 9.66 | 11.76 | 8.03 | 8.24 |
| — | +193.5% | -4.3% | -11.3% | -11.2% | +37.7% | +25.2% | +22.5% | -66.3% | -79.0% | -79.6% | -82.3% | -54.4% | -63.5% | -65.3% | -32.9% | -8.2% | +16.2% | +24.8% | -42.7% | -44.3% | |
| Quick Ratio | 0.76 | 2.32 | 0.72 | 0.76 | 0.73 | 0.69 | 0.71 | 0.84 | 0.84 | 0.44 | 0.54 | 0.67 | 2.56 | 2.65 | 3.32 | 4.63 | 6.83 | 8.78 | 10.79 | 7.28 | 7.76 |
| — | +234.3% | +1.0% | -10.4% | -14.1% | +56.6% | +31.4% | +25.7% | -66.9% | -83.3% | -83.7% | -85.5% | -62.6% | -69.8% | -69.2% | -36.4% | -12.0% | +5.6% | +14.5% | -48.1% | -47.6% | |
| Interest Coverage | -1.64 | 4.40 | 0.28 | 0.57 | -2.91 | -0.06 | -1.09 | -0.75 | -2.87 | -4.56 | -0.67 | -1.06 | -5.59 | -12.06 | -10.96 | -2.06 | -3.50 | -15.04 | -22.20 | -2.32 | -90.61 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ASND stock.
Ascendis Pharma A/S's current P/E is -55.9x. The average P/E over the last 2 quarters is 13.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ascendis Pharma A/S's current operating margin is -18.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ascendis Pharma A/S's business trajectory between earnings reports.